Tanvex BioPharma Inc (6541) — Working Capital to Net Assets Ratio
Tanvex BioPharma Inc (6541) has a Working Capital to Net Assets ratio of 5.1% as of March 2026. Working capital of NT$276.13 Million (current assets of NT$1.10 Billion minus current liabilities of NT$827.46 Million) is measured against net assets of NT$5.36 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See 6541 FCF to total liabilities ratio to measure the company's free cash flow as a share of total liabilities.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Tanvex BioPharma Inc Working Capital to Net Assets (2013–2025)
This chart shows how Tanvex BioPharma Inc's Working Capital to Net Assets ratio has evolved across 13 annual periods from 2013 to 2025. As of March 2026, the ratio stands at 5.1%, reflecting working capital of NT$276.13 Million against net assets of NT$5.36 Billion TWD. See Tanvex BioPharma Inc defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Annual Working Capital to Net Assets for Tanvex BioPharma Inc (2013–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for Tanvex BioPharma Inc from 2013 to 2025, covering 13 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see Tanvex BioPharma Inc market cap and net worth.
| Year | WC/NA Ratio | Working Capital (TWD) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 12.3% | NT$697.52 Million | NT$5.69 Billion | NT$1.50 Billion | NT$799.66 Million | ▼ -24.4 pp |
| 2024 | 36.7% | NT$327.48 Million | NT$893.31 Million | NT$675.62 Million | NT$348.14 Million | ▲ +7.4 pp |
| 2023 | 29.3% | NT$240.48 Million | NT$821.11 Million | NT$604.21 Million | NT$363.73 Million | ▼ -23.9 pp |
| 2022 | 53.2% | NT$740.43 Million | NT$1.39 Billion | NT$1.04 Billion | NT$303.29 Million | ▼ -23.8 pp |
| 2021 | 77.1% | NT$2.15 Billion | NT$2.79 Billion | NT$2.40 Billion | NT$248.51 Million | ▲ +4.2 pp |
| 2020 | 72.9% | NT$1.91 Billion | NT$2.62 Billion | NT$2.26 Billion | NT$353.10 Million | ▼ -4.1 pp |
| 2019 | 77.0% | NT$2.33 Billion | NT$3.03 Billion | NT$2.60 Billion | NT$270.45 Million | ▼ -5.7 pp |
| 2018 | 82.7% | NT$3.49 Billion | NT$4.21 Billion | NT$3.70 Billion | NT$209.46 Million | ▲ +2.4 pp |
| 2017 | 80.3% | NT$3.01 Billion | NT$3.75 Billion | NT$3.18 Billion | NT$164.70 Million | ▲ +4.2 pp |
| 2016 | 76.1% | NT$2.72 Billion | NT$3.57 Billion | NT$2.95 Billion | NT$233.15 Million | ▲ +29.3 pp |
| 2015 | 46.8% | NT$678.07 Million | NT$1.45 Billion | NT$780.47 Million | NT$102.40 Million | ▲ +17.4 pp |
| 2014 | 29.4% | NT$173.55 Million | NT$589.64 Million | NT$218.43 Million | NT$44.88 Million | ▼ -0.3 pp |
| 2013 | 29.8% | NT$120.18 Million | NT$403.64 Million | NT$182.77 Million | NT$62.59 Million | — |